Objectives/Introduction: Immune mediated pancreatic injury is a well-known side effect of immune checkpoint inhibitors (ICI) but there are lack of data regarding Pancreatic Adverse Events (PAEs) in patients with ICI related diabetes mellitus (ICI-DM).
Methods: We collected data from 31 subjects who were evaluated for ICI-DM at Mayo Clinic, Rochester from 2014 to 2023. PAEs were defined as new onset pancreatic disease (NOPD) or worsening of preexisting pancreatic disease (PPD) including acute or chronic pancreatitis, pancreatic cyst and pancreatic atrophy ± fatty replacement after ICI.
Results: We divided subjects into 2 cohorts: those with Cohort 1 with PAEs (n=14) and Cohort 2 without PAE (n=17) with more details in Table. There were no significant differences in age, BMI, PPD, pembrolizumab use, steroid use, HbA1c at DM onset or worsening of DM, follow-up time and mortality between the 2 cohorts. Cohort 1 experienced 16 PAEs; 9 subjects without PPD developed 11 new events (NOPD) and 5 subjects with PPD experienced PAEs. None of the other 4 subjects with PPD in cohort 2 experienced PAEs
Conclusion: In a single center, reasonable size cohort of ICI DM, pancreatic disease was induced or aggravated without increase in mortality. Further studies of this population are needed.
S. Rizvi: None. R. Kaur: None. C. Reid: None. D. Desjardins: None. Y.C. Kudva: Research Support; Dexcom, Inc. Other Relationship; Tandem Diabetes Care, Inc., Medtronic.
